v3.26.3
Revenue and other income - Additional information (Details)
1 Months Ended 6 Months Ended 12 Months Ended
Jan. 24, 2026
EUR (€)
Dec. 31, 2023
EUR (€)
Mar. 31, 2023
EUR (€)
option
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Revenue from collaboration and licensing agreements       € 3,115,000 € 1,671,000  
Advance received - exclusive license   € 13,300,000        
Payments for research work   1,700,000       € 1,700,000
Milestone payment received - option exercised   15,000,000        
Monalizumab agreement            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Decrease in revenue from contracts with customers       (100,000)    
Revenue from collaboration and licensing agreements       0 56,000  
IPH5201 agreement, with AstraZeneca            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Revenue from collaboration and licensing agreements       0 0  
IPH5201 agreement, with AstraZeneca            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Revenue from collaboration and licensing agreements       417,000 916,000  
Agreement with Sanofi, 2016            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Revenue from collaboration and licensing agreements       0 € 0  
Milestone payment received       € 0    
Agreements with Genzyme for NK Cell engages            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Number of target options | option     2      
Advance received     € 25,000,000      
Advance received - exclusive license     18,500,000      
Payments for research work     € 1,500,000      
Research activities performance period     3 years      
Payments for target options     € 5,000,000      
Number of exclusive options granted | option     2      
Agreements with Sanofi for NK Cell engages            
Disclosure of disaggregation of revenue from contracts with customers [line items]            
Revenue from collaboration and licensing agreements € 2,500,000 € 2,500,000